Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Webcast ImageWebcast - Replay
The Medicines Company at Oppenheimer Healthcare Conference
12/10/14 at 9:10 a.m. ET
Webcast ImageWebcast - Replay
The Medicines Company at Credit Suisse Healthcare Conference
11/12/14 at 1:00 p.m. MT
Webcast ImageWebcast - Replay
The Medicines Company Investor & Analyst Day
11/05/14 at 8:25 a.m. ET
Webcast ImageWebcast - Replay
Q3 2014 The Medicines Company Earnings Conference Call
10/22/14 at 8:30 a.m. ET
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$27.31
Change (%) Stock is Up 0.27 (1.00%)
Volume2,332,696
Data as of 12/19/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
12/18/14The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two Cardiovascular Products in China
SciClone to Promote Potential Hospital Market Leaders in China, ANGIOMAX® (bivalirudin) and CLEVIPREX® (clevidipine) PARSIPPANY, N.J. & FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 18, 2014-- The Medicines Company (Nasdaq:MDCO), a global biopharmaceutical company focused on hospital care, and SciClone Pharmaceuticals (Nasdaq: SCLN), a U.S. based, China focused specialty pharmaceutical company, today announced the establishment of a strategic partne... 
Printer Friendly Version
12/11/14Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a Subcutaneously Administered Investigational RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 11, 2014--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and The Medicines Company (Nasdaq: MDCO), a global biopharmaceutical company focused on hospital care, announced today that Alnylam has initiated a Phase 1 clinical trial with ALN-PCSsc, an investigational agent for the treatment of hypercholesterolemia. The initiation of this trial has triggered a $10 million milestone from The Medicines Company to Al... 
Printer Friendly Version
12/08/14The Medicines Company to Participate in Oppenheimer 25th Annual Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Dec. 8, 2014-- The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Oppenheimer 25th Annual Healthcare Conference in New York, NY on Wednesday, December 10th at 9:10 AM EST. The session will be webcast with a link available at The Medicines Company’s website http://www.themedicinescompany.com. About The Medicines Company The Medicines Company's purpose is to save lives, allev... 
Printer Friendly Version
11/16/14The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters and Was Well-Tolerated in Healthy and Coronary Artery Disease (CAD) Patients
Findings presented at 2014 AHA Annual Scientific Sessions Meeting in Chicago support further development of MDCO-216 as potential treatment for reducing atherosclerotic disease PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 16, 2014-- The Medicines Company (NASDAQ:MDCO) today presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key ... 
Printer Friendly Version
Upcoming Events
There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.